Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders
Your vote is important no matter how many votes you hold. Vote today
Shareholders who have questions or need assistance with voting their shares should contact
Shareholder Meeting Details
The Company's annual general meeting of shareholders (the "Meeting") will be held virtually on
Oncolytics has retained
YOUR VOTE IS IMPORTANT. VOTE YOUR SHARES FOR ONCOLYTICS' DIRECTOR NOMINEES AND MEETING RESOLUTIONS AS SOON AS POSSIBLE.
Shareholders are encouraged to read the Circular and vote their shares as soon as possible. The deadline for voting your shares is
Oncolytics' board of directors recommends that shareholders vote FOR all of the director nominees and meeting resolutions.
Shareholder Questions
Shareholders who have any questions or require assistance with voting may contact the Company's proxy solicitation agent and shareholder communications advisor:
Toll Free: 1-877-452-7184 (for shareholders in
International: +1 416-304-0211 (for shareholders outside
By Email: assistance@laurelhill.com
About
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.
Company Contact Director of IR & Communication +1-858-886-7813 | Investor Relations for Oncolytics +1-917-679-9282 |
Logo: https://mma.prnewswire.com/media/1808285/3981527/Oncolytics_Biotech_Grey.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-filing-and-mailing-of-the-management-information-circular-in-connection-with-the-annual-general-meeting-of-shareholders-301795243.html
SOURCE Oncolytics Biotech® Inc.